Roger M. Perlmutter is the former executive vice president of Merck & Co. and former president of Merck Research Laboratories. He is currently a non-executive director of Merck Research Laboratories.[1][2]
In 1989, he was the founding chair of the immunology department. His research focused on the role of tyrosine kinase signaling and its role in lymphocyte development and immunology.[5] During that time he was also a Howard Hughes Medical Institute (HHMI) investigator.[6][7]
In 1997, Perlmutter joined Merck Research Laboratories as the executive vice president of basic and preclinical research. At the time, Perlmutter was not chosen to replace Edward Scolnik as president of Merck Research Laboratories; that position went instead to Peter S. Kim, previously of the Massachusetts Institute of Technology. In 2001, Perlmutter left Merck and joined Amgen as the executive vice president and head of R&D from January 2001 to February 2012. In 2013, he replaced Peter S. Kim as the executive vice president and president of Merck Research Laboratories.[8] In 2020, he retired from Merck and was replaced by Dean Y. Li.[9] In 2021 he became CEO of a microscopy start-up, Eikon Therapeutics.[10]
^Turner, JM; Brodsky, MH; Irving, BA; Levin, SD; Perlmutter, RM; Littman, DR (Mar 9, 1990). "Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs". Cell. 60 (5): 755–65. doi:10.1016/0092-8674(90)90090-2. PMID2107025. S2CID205019980.